Sorcin can trigger pancreatic cancer-associated new-onset diabetes through the secretion of inflammatory cytokines such as serpin E1 and CCL5

A rise in blood glucose is an early warning sign of underlying pancreatic cancer (PC) and may be an indicator of genetic events in PC progression. However, there is still a lack of mechanistic research on pancreatic cancer-associated new-onset diabetes (PCAND). In the present study, we identified a gene SRI , which possesses a SNP with the potential to distinguish PCAND and Type 2 diabetes mellitus (T2DM), by machine learning on the basis of the UK Biobank database. In vitro and in vivo, sorcin overexpression induced pancreatic β-cell dysfunction. Sorcin can form a positive feedback loop with STAT3 to increase the transcription of serpin E1 and CCL5, which may directly induce β-cell dysfunction. In 88 biopsies, the expression of sorcin was elevated in PC tissues, especially in PCAND samples. Furthermore, plasma serpin E1 levels are higher in peripheral blood samples from PCAND patients than in those from T2DM patients. In conclusion, sorcin may be the key driver in PCAND, and further study on the sorcin-STAT3-serpin E1/CCL5 signaling axis may help us better understand the pathogenesis of PCAND and identify potential biomarkers. Sorcin Identified as Key Driver in Pancreatic Cancer Diabetes Pancreatic cancer, a lethal disease with a low survival rate, can be better managed with early detection. Researchers investigated the connection between pancreatic cancer and newly developed diabetes, pinpointing the SRI gene and its protein, sorcin, as crucial elements. They used machine learning to examine genetic data from the UK Biobank, focusing on Single Nucleotide Polymorphisms to differentiate between diabetes associated with pancreatic cancer and type 2 diabetes. The research included lab and live experiments to understand how sorcin impacts pancreatic β-cells and contributes to diabetes in pancreatic cancer patients. Researchers believe that focusing on the sorcin-STAT3 pathway could provide new possibilities for early diagnosis and treatment of pancreatic cancer. This study is a significant advancement in understanding the molecular links between pancreatic cancer and diabetes, potentially leading to earlier detection and better patient outcomes. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.